Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03291938 · ClinicalTrials.gov registry record · Phase 1
IACS-010759 in Advanced Cancers
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03291938: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT03291938 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03291938, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of oxidative phosphorylation inhibitor IACS-010759 (IACS-010759) in treating patients with lymphoma that has come back (relapsed) or does not respond to treatment (refractory) or solid tumors that have spread to other places in the body (advanced/metastatic) or cannot be removed by surgery (unresectable). IACS-010759 may stop the growth of cancer or tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER Pharmacokinetic Study
- OTHER Pharmacodynamic Study
- DRUG Oxidative Phosphorylation Inhibitor IACS-010759
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2017-11-13 |
| Est. Completion | 2020-11-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03291938
The ClinicalTrials.gov registry entry for NCT03291938 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Pharmacokinetic Study is the first listed.
NCT03291938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03291938 about?
NCT03291938 is a clinical study titled "IACS-010759 in Advanced Cancers". This phase I trial studies the side effects and best dose of oxidative phosphorylation inhibitor IACS-010759 (IACS-010759) in treating patients with lymphoma that has come back (relapsed) or does not respond to treatment (refractory) or solid tumors that have spread to other places in the body (adva...
What is the current status of trial NCT03291938?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2017-11-13. Estimated completion is 2020-11-23.
What interventions are being tested in trial NCT03291938?
The interventions under investigation include: Pharmacokinetic Study (OTHER), Pharmacodynamic Study (OTHER), Oxidative Phosphorylation Inhibitor IACS-010759 (DRUG).
Who is sponsoring clinical trial NCT03291938?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.